Glucose effectiveness describes the restraining effect of hyperglycemia on endogenous glucose production (EGP), which is lost in type 2 diabetes (T2D). Since central nervous system KATP channels likely regulate EGP in humans and rats, we examined whether these channels contribute to glucose effectiveness. Paired 4-hour hyperglycemic ’pancreatic clamp’ studies were performed in 9 healthy humans (age 37 ± 15 years; BMI 26 ± 4 kg/m2) 3 hours following glyburide 10 mg (GLB) or placebo (PLC). With PLC, hyperglycemia suppressed EGP by 59% (euglycemia: 2.38 ± 0.229 vs. hyperglycemia: 0.98 ± 0.17, p < 0.001). GLB resulted in 46% less suppression of EGP by hyperglycemia from baseline euglycemia compared to PLC (GLB: 1.56 ± 0.29 mg/kg/min vs. PLC: 0.98 ± 0.17 mg/kg/min, p = 0.047). To confirm that GLB’s effects were centrally mediated, parallel hyperglycemic studies were conducted in normal rats after oral gavage of normal saline (NS) (n=8), GLB (n=14), and oral GLB with intracerebroventricular (ICV) infusion of KATP channel agonist diazoxide (DZX) (n=8). GLB attenuated hyperglycemia’s suppressive effect on EGP (GLB: 9.4 ± 0.3 mg/kg/min vs. NS: 6.9 ± 0.3 mg/kg/min; p = 0.047), while ICV DZX abolished the effects of GLB (DZX + GLB: 5.5 ± 0.5 mg/kg/min vs. GLB, p = 0.003)(Figure 1). This suggests that ∼50% of the suppression of EGP by hyperglycemia is mediated by central KATP channels. Targeting these channels may offer a new therapeutic approach to improve glycemic control in T2D.


W.G. Mitchell: None. E. Lontchi-Yimagou: None. S.A. Reda: None. M. Carey: None. K. Zhang: None. S. Aleksic: None. D. Huffman: None. M. Hawkins: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at